Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Sig... Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. Show more
β Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells ββ Subcutaneous AK006 was well-tolerated with a favorable safety profile...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0167 | 2.48511904762 | 0.672 | 0.7 | 0.6343 | 288945 | 0.65611618 | CS |
4 | 0.0787 | 12.9016393443 | 0.61 | 0.7255 | 0.535 | 348557 | 0.59918998 | CS |
12 | -0.0013 | -0.188405797101 | 0.69 | 0.96 | 0.535 | 343611 | 0.7013136 | CS |
26 | -0.4513 | -39.5877192982 | 1.14 | 1.51 | 0.535 | 482136 | 0.96365024 | CS |
52 | -1.3513 | -66.2401960784 | 2.04 | 3.405 | 0.535 | 820380 | 1.49449823 | CS |
156 | -105.7413 | -99.3529080147 | 106.43 | 112.87 | 0.535 | 1353291 | 6.75385394 | CS |
260 | -65.9113 | -98.9659159159 | 66.6 | 157.98 | 0.535 | 922077 | 17.57675889 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.